Improvement of efficacy of immune checkpoint blockade (ICB) remains a major clinical goal. Association of ICB with immunomodulatory epigenetic drugs is an option. However, epigenetic inhibitors show a heterogeneous landscape of activities. Analysis of transcriptional programs induced in neoplastic cells by distinct classes of epigenetic drugs may foster identification of the most promising agents.
Landscape of immune-related signatures induced by targeting of different epigenetic regulators in melanoma: implications for immunotherapy / Anichini, A., Molla, A., Nicolini, G., Perotti, V.E., Sgambelluri, F., Covre, A., Fazio, C., Lofiego, M.F., Di Giacomo, A.M., Coral, S., Manca, A., Sini, M.C., Pisano, M., Noviello, T., Caruso, F., Brich, S., Pruneri, G., Maurichi, A., Santinami, M., Ceccarelli, M., et al.. - In: JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH. - ISSN 1756-9966. - 41:1(2022). [10.1186/s13046-022-02529-5]
Landscape of immune-related signatures induced by targeting of different epigenetic regulators in melanoma: implications for immunotherapy
Palmieri, Giuseppe;
2022-01-01
Abstract
Improvement of efficacy of immune checkpoint blockade (ICB) remains a major clinical goal. Association of ICB with immunomodulatory epigenetic drugs is an option. However, epigenetic inhibitors show a heterogeneous landscape of activities. Analysis of transcriptional programs induced in neoplastic cells by distinct classes of epigenetic drugs may foster identification of the most promising agents.| File | Dimensione | Formato | |
|---|---|---|---|
|
Anichini JECCR 2022.pdf
accesso aperto
Descrizione: File pdf
Tipologia:
Versione editoriale (versione finale pubblicata)
Licenza:
Creative commons
Dimensione
6.44 MB
Formato
Adobe PDF
|
6.44 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
